Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox"

Lung Cancer

Volumn 90, Issue 2, 2015, Pages 161-166

  Arrieta, Oscar ^a   Ramírez Tirado, Laura Alejandra ^a   Báez Saldaña, Renata ^b   Peña Curiel, Omar ^a   Soca Chafre, Giovanny ^a   Macedo Perez, Eleazar Omar ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Carcinoma; ErbB 1; Gene expression; Hispanic Americans; Human; KRAS Protein; Mutation; Non Small Cell Lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; RAS PROTEIN; SMOKE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; GENE MUTATION; HISPANIC; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEXICO; NATIONAL HEALTH ORGANIZATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SMOKING; ADOLESCENT; ADVERSE EFFECTS; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SMOKE; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HISPANIC AMERICANS; HUMANS; LUNG NEOPLASMS; MALE; MEXICO; MIDDLE AGED; MUTATION; PROGNOSIS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKE; SMOKING; YOUNG ADULT;

EID: 84955304728     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.08.010     Document Type: Article

References (41)

1. Ferlay I., Soerjomataram R., Dikshit S., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136:E359-E386.
2. Arrieta O., Guzmán-de Alba E., Alba-López L.F., et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev. Invest. Clin. 2013, 65(March (Suppl. 1)):S5-84.
3. Patel J.D., Socinski M.A., Garon E.B., et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2013, 31(December (34)):4349-4357. Epub 2013 October 21. 10.1200/JCO. 2012.47.9626.
4. Lee J.K., Hahn S., Kim D.W., et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. J. Am. Med. Assoc. 2014, 311(April (14)):1430-1437. 10.1001/jama.2014.3314.
5. Sequist L.V., Yang J.C.-H., Yamamoto N., et al. Phase III. study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013, 31:3327-3334.
6. Patel M.I., Schupp C.W., Gomez S.L., et al. How do social factors explain outcomes in non-small-cell lung cancer among Hispanic in California? Explaining the Hispanic Paradox. J. Clin. Oncol. 2013, 31:1-8.
7. Lara M.S., Brunson A., Wun T., Tomlinson B., et al. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer 2014, 85:264-269.
8. Lara-Medina F., Pérez-Sánchez V., Saavedra-Perez D., et al. Triple negative breast cancer in Hispanic patients. Cancer 2011, 17:3658-3669.
9. Arrieta O., Cardona A.F., Bramuglia F., et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. 2011, 6:1955-1959.
10. Rodríguez-Cuevas S., Macías C.G., Franceschi D., et al. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001, 91(February (15)):863-868.
11. Ettinger, DS, Akerley, W, Borghaei, H, et al. Non-small cell lung cancer. NCCN (National Comprehensive Cancer Network) 2014.
12. Ding Q., Cheng X., Yang L., et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J. Thorac. Dis. 2014, 6:677-683.
13. Saeed A.M., Toonkel R., Glassberg M.K., et al. The influence of Hispanic ethnicity on no small cell lung cancer history and patient survival: an analysis of the survival, epidemiology, and end results database. Cancer 2012, 118. 4495-01.
14. Arrieta O., Martinez-Barrera L., Treviño S., et al. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J. Thorac. Oncol. 2008, 3:887-893.
15. Arrieta O., Campos-Parra A.D., Zuloaga C., et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J. Thorac. Oncol. 2012, 7:1228-1234.
16. Delgado J., Martinez L.M., Sánchez T.T., et al. Lung cancer pathogenesis associated with wood smoke exposure. Chest 2005, 128(July (1)):124-131.
17. García-Sancho Figueroa C., Fernández-Plata R., Rivera-de la Garza M.S., et al. Humo de leía como factor de riesgo de cáncer pulmonar en poblaciñn hospitalizada no fumadora. Neumol. Cir. Torax. 2012, 71(October-Dececember (4):325-332.
18. Yu Y.H., Liao C.C., Hsu W.H., et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J. Thorac. Oncol. 2011, 6:32-37.
19. Luo Y.H., Wu C.H., Wu W.S., et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J. Thorac. Oncol. 2012, 7:299-305.
20. Bae J.M., Li Z.M., Shin M.H., et al. Pulmonary tuberculosis and lung cancer risk in current smokers: the Seoul male cancer cohort study. Korean Med. Sci. 2013, 28:896-900.
21. Sisti J., Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors?. Int. J. Cancer 2012, 131:265-275.
22. Pairon J.C., Andujar P., Rinaldo M., et al. Asbestos exposure, pleural plaques, and the risk of death from lung cancer. Am. J. Respir. Crit. Care Med. 2014, 190:1413-1420.
23. Serrier H., Sultan-Taieb H., Luce D., et al. Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France. Eur. J. Health Econ. 2014, 15:661-673.
24. Wei S., Wang L.E., McHugh M.K., et al. Genome-wide gene-environment interaction analysis for asbestos exposure in lung cancer susceptibility. Carcinogenesis 2012, 33:1531-1537.
25. Hystad Brauer M., Demers P.A., et al. Geographic variation in radon and associated lung cancer risk in Canada. Can. J. Public Health 2014, 105:e4-e10.
26. Zhukovsky M., Varaksin A., Pakholkina O. Statistical analysis of observational study of the influence of radon and other risk factors on lung cancer incidence. Radiat. Prot. Dosim. 2014, 160:108-111.
27. Fajersztajn L., Veras M., Barrozo L.V., et al. Air pollution: a potentially modifiable risk factor for lung cancer. Nat. Rev. Cancer 2013, 13:674-678.
28. Cetin K., Ettinger D.S., Hei Y. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program. Clin. Epidemiol. 2011, 3.
29. Stojsic J., Radojicic J., Markovic J., et al. Gender and age trends of histological types of lung cancer in a 20-year period: pathological perspective. J. BUON 2010, 15:136-140.
30. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2011 2014, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April.
31. Guerrero-López C.M., Muños Hernández J.A., de Miera Juárez B.S., et al. Evidencia para la política pública en salud: Consumo de tabaco en México 2000-2012:los beneficios de su reducción. ENSANUT 2012.
32. Agaku, I.T., King, B.A., Dube, S.R. Current Cigarette Smoking Among Adults-United States, 2005-2012. Centers for Disease Control and Prevention MMWR/January 17, 2014/Vol. 63/No. 2.
33. SINAVE 2007 (Sistema Nacional De Vigilancia Epidemiológica de México) Plataforma Única de información. Módulo Tuberculosis, Ene-Dic 2006 y 2007.
34. Arrieta O., Rios T., rejo M.A., Michel R.M. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung patients. J. Thorac. Oncol. 2009, 4(August (8)):1043. 10.1097/JTO.0b013e3181ae2497.
35. Panamerican Health Organization. La tuberculosis en la Región de las Américas. Informe Regional 2012. Epidemiología, control y financiamiento 2012.
36. Oxnard G.R., Lo P.C., Nishino M., Dahlberg S.E., et al. Natural history and molecular characteristics of lung s harboring EGFR exon 20 insertions. J. Thorac. Oncol. 2013, 8(Febuary (2)):179-184. 10.1097/JTO.0b013e3182779d18.
37. Arrieta O., Cardona A.F., Martín C., et al. pdated frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) in Latin America: the Latin-America Consortium for the Investigation fo Lung Cancer (CLICap). J. thorac. Oncol. 2015, (in press).
38. Broët P., Dalmasso C., Tan E.H., et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin. Cancer Res. 2011, 17(June (11)):3542-3550. CCR-10-2185. 10.1158/1078-0432.
39. Johnson B.E., Kabbinavar F., Fehrenbacher L., et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2013, 31:3926-3934.
40. Campos-Parra A.D., Zuloaga C., Vazquez-Manriquez V., et al. Kras mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non?small cell lung cancer. Am. J. Clin. Oncol. 2013, 28(March).
41. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-995.